The role of immunological markers in the diagnosis of colorectal cancer

Czech version

Authors: A. Erbenová ¹; P. Horák ¹; M. Slavíková Červinková ¹; J. Čížková ²; P. Šuhaj ³
Authors‘ workplace: Chirurgická klinika 1. LF UK a FN Bulovka a IPVZ, Praha ¹; Katedra radiobiologie, Vojenská LF, Univerzita obrany, Hradec Králové3 Ústav patologie a molekulární medicíny, 3. LF UK a Fakultní Thomayerova nemocnice, Praha ²
Published in: Klin Onkol 2026; 39(Supplementum 2): 126-129
Category: Article
doi: https://doi.org/10.48095/ccko20262S126

Overview

Introduction: Colorectal cancer (CRC) remains one of the most common solid malignancies in the Western population. Despite advances in screening, diagnostics, and treatment, there are still no highly specific tests for early diagnosis or biomarkers that can reliably identify high-risk patients or monitor disease progression more effectively than currently established tumor markers. The pathogenesis of CRC is closely associated with chronic inflammation, oxidative stress, and remodeling of the tumor microenvironment. The present study focuses on several biomarkers selected based on available literature data and their close association with these processes. LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1), RAGE (receptor for advanced glycation end products), HMGB1 (high mobility group box 1), and matrix metalloproteinase-19 (MMP-19) are involved in the regulation of inflammatory signaling pathways, angiogenesis, and extracellular matrix degradation. The aim of this study was to test the hypothesis that the expression of these markers is significantly increased in patients with CRC compared with healthy controls. Methods: The study included intestinal tissue samples obtained from 34 patients with CRC and 21 control subjects who underwent intestinal resection at our institution for non-neoplastic and non-inflammatory conditions. In CRC patients, three tissue compartments were analyzed –⁠ macroscopically normal tissue, the tumor transition zone, and tumor tissue. Samples were processed using immunohistochemical methods, and marker positivity was assessed across several cellular populations. Results: Statistically significant differences in the expression of selected markers were identified between the control group and patients with CRC. LOX-1 demonstrated increased expression in the epithelial and vascular structures of tumor tissue. RAGE expression was elevated in vascular structures and within the tumor transition zone, suggesting its involvement in the inflammatory tumor microenvironment. MMP-19 expression was most pronounced at the tumor-normal tissue interface, consistent with its role in extracellular matrix remodeling and tumor invasion. Conclusions: Our findings support the involvement of the investigated markers in the pathogenesis of CRC. Their expression may contribute not only to a better understanding of CRC biology but also to the identification of potential prognostic biomarkers and therapeutic targets.

Keywords:

colorectal cancer – biomarkers – tumor microenvironment – LOX-1 – RAGE – MMP-19 – HMGB1

Sources

1. Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians 2024; 74 (3): 229–263. doi: 10.3322/caac.21834.

2. Pellino G, Gallo G, Pallante P et al. Noninvasive biomarkers of colorectal cancer: role in diagnosis and personalised treatment perspectives. Gastroenterol Res Pract 2018; 2018 : 2397863. doi: 10.1155/2018/2397863.

3. Patel JN, Fong MK, Jagosky M. Colorectal cancer biomarkers in the era of personalized medicine. J Pers Med 2019; 9 (1): 3. doi: 10.3390/jpm9010003.

4. Azizian-Farsani F, Abedpoor N, Hasan Sheikhha M et al. Receptor for advanced glycation end products acts as a fuel to colorectal cancer development. Front Oncol 2020; 10 : 552283. doi: 10.3389/fonc.2020.552283.

5. Murdocca M, Mango R, Pucci S et al. The lectin-like oxidized LDL receptor-1: a new potential molecular target in colorectal cancer. Oncotarget 2016; 7 (12): 14765–14780. doi: 10.18632/oncotarget.7430.

6. Nakashima-Nakasuga C, Hazama S, Suzuki N et al. Serum LOX-1 is a novel prognostic biomarker of colorectal cancer. Int J Clin Oncol 2020; 25 (7): 1308–1317. doi: 10.1007/s10147-020-01673-2.

7. Katayama C, Yokobori T, Ozawa N et al. Low level of stromal lectin-like oxidized LDL receptor 1 and CD8+ cytotoxic T-lymphocytes indicate poor prognosis of colorectal cancer. Cancer Rep 2021; 4 (4): e1364. doi: 10.1002/cnr2.1364.

8. Atkinson SJ, Ward RV, Reynolds JJ et al. Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. Biochem J 1992; 288 (Pt 2): 605–611. doi: 10.1042/bj2880605.

9. Jost M, Folgueras AR, Frérart F et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res 2006; 66 (10): 5234–5241. doi: 10.1158/0008-5472.

10. Chan KC, Ko JMY, Lung HL et al. Catalytic activity of Matrix metalloproteinase-19 is essential for tumor suppressor and anti-angiogenic activities in nasopharyngeal carcinoma. Int J Cancer 2011; 129 (8): 1826–1837. doi: 10.1002/ijc.25855.

11. Brauer R, Beck IM, Roderfeld M et al. Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen. BMC Biochem 2011; 12 : 38. doi: 10.1186/1471-2091-12-38.

12. Horak P, Suhaj P, Matej R et al. Potential novel markers in IBD and CRC diagnostics. Are MMP-19 and RAGE promising candidates? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2022; 166 (4): 380–385. doi: 10.5507/bp.

13. Cervinková M, Horák P, Kanchev I et al. Differential expression and processing of matrix metalloproteinase 19 marks progression of gastrointestinal diseases. Folia Biol (Praha) 2014; 60 (3): 113–122. doi: 10.14712/fb2014060030113.

14. Süren D, Yıldırım M, Demirpençe Ö et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit 2014; 20 : 530–537. doi: 10.12659/MSM.890531.